Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 9/20 | 0.53 |
| ▸ | SELP | P16109 | 1/20 | 0.45 |
| ▸ | SELE | P16581 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6003048 | 1.00 | CASR (0.64) | CASRKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11038416 | 0.87 | LTA4H (0.61) | KDM4EALDH1A1LMNASMN1; SMN2LTA4H | |
| SCHEMBL177265 | 0.85 | LTA4H (0.52) | CASRLTA4HHCAR2 | |
| SCHEMBL2517851 | 0.85 | SELP (0.56) | CASRKDM4EALDH1A1SMN1; SMN2LTA4H | |
| SCHEMBL6005172 | 0.82 | CASR (0.67) | CASRKDM4EALDH1A1SMN1; SMN2LTA4H | |
| SCHEMBL177554 | 0.82 | CASR (0.67) | CASRKDM4EALDH1A1SMN1; SMN2LTA4H | |
| SCHEMBL6005527 | 0.81 | CASR (0.57) | CASRLTA4H | |
| SCHEMBL3633756 | 0.80 | SMN1; SMN2 (0.66) | CASRKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4289827 | 0.79 | KDM4E (0.64) | CASRKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14471633 | 0.78 | CASR (1.00) | CASRKDM4EALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2345636-B1 | CASR AGONIST | AJINOMOTO KK (JP) | 2016-03-30 | — | — | EP | claimed |
| EP-2345636-B1 | CASR AGONIST | AJINOMOTO KK (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-9174932-B2 | CaSR agonists | AJINOMOTO CO., INC. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-9000208-B2 | Glutamate derivatives or salts thereof | AJINOMOTO CO., INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8877739-B2 | Prophylactic agent or therapeutic agent for diabetes or obesity | AJINOMOTO CO., INC. (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20140303122-A1 | CASR AGONISTS | AJINOMOTO CO., INC. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8796485-B2 | CaSR agonists | AJINOMOTO CO., INC. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | AJINOMOTO CO., INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2554165-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | Ajinomoto Co., Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| EP-2551262-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | Ajinomoto Co., Inc. (JP) | 2013-01-30 | — | — | EP | disclosed |
| US-20130017603-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | AJINOMOTO CO., INC. (JP) | 2013-01-17 | — | — | US | disclosed |
| US-20110251418-A1 | CASR AGONISTS | AJINOMOTO CO., INC. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2345636-A1 | CASR AGONIST | Ajinomoto Co., Inc. (JP) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017603-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | CASR, GIPR, GRPR | CASR 1/4885KDM4E 4016/4885ALDH1A1 2603/4885 |
| US-20140303122-A1 | CASR AGONISTS | CASR, GIPR, GRIK5 | CASR 1/4885KDM4E 3886/4885ALDH1A1 2705/4885 |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | GPR119, GIPR, CASR | CASR 3/4885KDM4E 4756/4885ALDH1A1 2335/4885 |
| US-20110251418-A1 | CASR AGONISTS | CASR, GIPR, GRIK5 | CASR 1/4885KDM4E 3886/4885ALDH1A1 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.